A61K 31/7042
Compounds having saccharide radicals and heterocyclic rings
A61K31/7042 (Compounds having saccharide radicals and heterocyclic rings) appears on 8,333 US grants and 16,562 published applications in this corpus.
Search patents in A61K- Granted patents
- 8,333
- Published applications
- 16,562
- Assignees
- 5,336
- Inventors
- 26,502
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 4 | 0 |
| 1989 | 9 | 0 |
| 1990 | 5 | 0 |
| 1991 | 1 | 0 |
| 1992 | 8 | 0 |
| 1993 | 8 | 0 |
| 1994 | 4 | 0 |
| 1995 | 22 | 0 |
| 1996 | 55 | 0 |
| 1997 | 107 | 0 |
| 1998 | 94 | 0 |
| 1999 | 91 | 0 |
| 2000 | 83 | 0 |
| 2001 | 99 | 45 |
| 2002 | 103 | 222 |
| 2003 | 129 | 344 |
| 2004 | 87 | 382 |
| 2005 | 97 | 465 |
| 2006 | 150 | 480 |
| 2007 | 111 | 458 |
| 2008 | 137 | 399 |
| 2009 | 133 | 432 |
| 2010 | 174 | 489 |
| 2011 | 203 | 523 |
| 2012 | 255 | 471 |
| 2013 | 368 | 724 |
| 2014 | 435 | 862 |
| 2015 | 410 | 806 |
| 2016 | 455 | 908 |
| 2017 | 485 | 824 |
| 2018 | 443 | 718 |
| 2019 | 511 | 854 |
| 2020 | 509 | 881 |
| 2021 | 520 | 1030 |
| 2022 | 447 | 1022 |
| 2023 | 458 | 1014 |
| 2024 | 417 | 860 |
| 2025 | 422 | 788 |
| 2026 | 271 | 561 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Small molecule inhibitors of viral replication6 Oct 2026US 12,751,963 B2The Trustees of Princeton University
- Methods for treating pancreatic cancer and other solid tumors6 Oct 2026US 12,751,991 B2Lisata Therapeutics, Inc.
- Method of predicting therapeutic response and prognosis of metastatic breast cancer to chemotherapeutic agents, and treating metastatic breast cancer6 Oct 2026US 12,753,447 B2Samsung Life Public Welfare Foundation
- Aqueous pharmaceutical compositions comprising SGLT-2 inhibitors29 Sep 2026US 12,746,198 B2
- NiRAN interfering drugs for SARS-CoV-2 mutant therapy29 Sep 2026US 12,746,251 B2Atea Pharmaceuticals, Inc.
- Oral targeted nano delivery systems containing geniposide and preparation methods thereof8 Oct 2026US 2026/0306417 A1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
- Materials and methods for treating fungal infections8 Oct 2026US 2026/0306425 A1Virginia Tech Intellectual Properties, Inc.
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Pharmaceutical Combination of Oral Ivermectin and Mebendazole for Treatment of Refractory or Metastatic Pancreatic Cancers8 Oct 2026US 2026/0306458 A1
Most cited
By later US patents
- Method of treating androgen independent prostate cancer1,091US 9,040,574 B2Natrogen Therapeutics International, Inc. · 2015
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003